<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743287</url>
  </required_header>
  <id_info>
    <org_study_id>238KOA12F</org_study_id>
    <nct_id>NCT01743287</nct_id>
  </id_info>
  <brief_title>The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee</brief_title>
  <acronym>ABSOLUTE-OS</acronym>
  <official_title>A Six-month, Multi Center, Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of Imotun capsule in
      osteoarthritis of the knee
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a six-month, multicenter, randomized, double blind, parallel-group,placebo controlled
      study. Patients take Imotun capsules or placebo once a day, between the meals. Patients are
      allowed to take study drugs during the meal in the case of intolerant reflux of oil smell
      from GI. If patients do not tolerate the pain, they are able to take Celecoxib as a rescue
      medication during 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>100mm pain VAS</measure>
    <time_frame>24 weeks</time_frame>
    <description>assessment of the 100mm pain VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline Lequesne's index score at 24 weeks</measure>
    <time_frame>baseline, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline Lequesne's index score at 4 weeks</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm pain VAS at 4 weeks</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm pain VAS</measure>
    <time_frame>4 weeks</time_frame>
    <description>assessment of 100mm pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global assessment</measure>
    <time_frame>4 weeks</time_frame>
    <description>global assessment by physician and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>administration days of the rescue medication</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients who consumed the rescue medication</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Lequesne's index score at 8 weeks</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Lequesne's index score at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm pain VAS at 8 weeks</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm pain VAS at 16 weeks</measure>
    <time_frame>baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline 100mm pain VAS at 24 weeks</measure>
    <time_frame>baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm pain VAS</measure>
    <time_frame>8 weeks</time_frame>
    <description>assessment of 100mm pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100mm pain VAS</measure>
    <time_frame>16 weeks</time_frame>
    <description>assessment of 100mm pain VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global assessment</measure>
    <time_frame>8 weeks</time_frame>
    <description>global assessment by physician and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global assessment</measure>
    <time_frame>16 weeks</time_frame>
    <description>global assessment by physician and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global assessment</measure>
    <time_frame>24 weeks</time_frame>
    <description>global assessment by physician and patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dosing quantity of the rescue medication</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>rate of adverse event</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>laboratory test</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>medication history</measure>
    <time_frame>up to 24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Imotun capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imotun capsule placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imotun capsule</intervention_name>
    <description>Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks</description>
    <arm_group_label>Imotun capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imotun capsule placebo</intervention_name>
    <description>Imotun capsule placebo: per oral, a capsule a day during 24 weeks</description>
    <arm_group_label>Imotun capsule placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients who aged 40 or more and agreement with written informed
             consent

          -  Patients with osteoarthritis according to ACR criteria lasted for the past 3 months or
             more

          -  Patients with Kellgren &amp; Lawrence grade Ⅱ~Ⅲ on radiographs

          -  Patients with 40mm or higher 100mm Pain VAS on screening and baseline visit (based on
             more painful knee)

          -  Patients with Lequesne's index 5 or more on screening and baseline visit

        Exclusion Criteria:

          -  Patients who had taken SYSADOA within the past 3 months (Imotun, diacerein,
             s-adenosyl-methionone, JOINS, glucosamine, chondroitin and any other cartilage
             protective agents determined by investigator)

          -  Patients who experienced cartilage surgery within the past 5 years or arthroscope
             surgery within a year(one side or both)

          -  Patients who were treated with joint space injection within the past 3 months

          -  Patients who had taken NSAIDs including pain killers within 7 days (except, it is
             acceptable to enroll the study if the patients have wash out periods at least 7 days
             before randomization)

          -  Patients with hypersensitivity or allergy to the study or rescue medicine or those who
             have medical history.

          -  Patients with severe liver, kidney or cardiac diseases who are not acceptable for the
             study determined by investigator

          -  Patients with active peptic ulcer or GI bleeding.

          -  Pregnancy, nursing women or women of reproductive age who do not agree to the
             contraception.

          -  Patients with abuse of alcohol, illegal drugs or drug dependency

          -  Patients who were treated with another investigational product within the past 4 weeks

          -  All other patients who are not acceptable for the study determined by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung Chul Lee, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <state>Chungcheonbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>633-165</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang CHA medical center</name>
      <address>
        <city>Seongnam</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis of the knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

